Top Page
Towa Pharmaceutical Co
(OTC:4553)
Towa Pharmaceutical Co (4553) vs. iShares MSCI Japan ETF (EWJ)
Towa Pharmaceutical Co Business Overview & Revenue Model
Towa Pharmaceutical Co Financial Statement Overview
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 259.59B | 227.93B | 208.86B | 165.62B | 154.90B |
| Gross Profit | 94.73B | 81.38B | 72.71B | 70.19B | 65.45B |
| EBITDA | 48.05B | 35.54B | 24.92B | 29.49B | 30.35B |
| Net Income | 18.99B | 16.17B | 2.20B | 15.91B | 13.96B |
Balance Sheet | |||||
| Total Assets | 470.82B | 430.65B | 371.35B | 329.94B | 245.67B |
| Cash, Cash Equivalents and Short-Term Investments | 45.47B | 29.65B | 24.26B | 32.83B | 22.91B |
| Total Debt | 230.98B | 202.36B | 173.06B | 144.13B | 84.77B |
| Total Liabilities | 299.19B | 274.76B | 234.45B | 197.77B | 129.07B |
| Stockholders Equity | 171.63B | 155.89B | 136.89B | 132.17B | 116.60B |
Cash Flow | |||||
| Free Cash Flow | -5.33B | -31.11B | -27.93B | 8.55B | 2.13B |
| Operating Cash Flow | 23.40B | 8.21B | 2.54B | 22.13B | 12.01B |
| Investing Cash Flow | -31.29B | -40.39B | -30.28B | -59.73B | -9.10B |
| Financing Cash Flow | 21.57B | 35.41B | 17.48B | 46.54B | 184.00M |
Towa Pharmaceutical Co Technical Analysis
Towa Pharmaceutical Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | ¥82.49B | 8.74 | 3.32% | 9.83% | 86.18% | ||
75 Outperform | $139.28B | 11.68 | 8.77% | 2.95% | 31.19% | 72.28% | |
71 Outperform | ¥177.68B | 15.04 | 5.93% | 2.08% | 15.40% | 7.73% | |
70 Outperform | ¥146.51B | 9.16 | 9.60% | 2.12% | 11.11% | -5.42% | |
65 Neutral | $178.39B | 33.00 | 4.52% | 0.94% | 10.91% | 2.93% | |
65 Neutral | ¥201.90B | 220.16 | 1.35% | 3.52% | -95.28% | ||
47 Neutral | C$213.08M | -2.07 | -24.82% | 3.11% | 19.48% | -0.09% |
Towa Pharmaceutical Co Corporate Events
Towa Pharmaceutical Co., Ltd. reported its consolidated financial results for the three months ended June 30, 2025, showing a 4.1% increase in net sales compared to the previous year. However, the company experienced a significant decline in profits, with operating profit decreasing by 8.2% and ordinary profit falling by 54.0%. The forecast for the fiscal year ending March 31, 2026, anticipates a 7.9% increase in net sales and a 16.2% rise in operating profit, despite a projected decrease in ordinary profit and profit attributable to owners of the parent. This mixed financial performance may impact the company’s market positioning and stakeholder confidence.
The most recent analyst rating on (JP:4553) stock is a Hold with a Yen3200.00 price target. To see the full list of analyst forecasts on Towa Pharmaceutical Co stock, see the JP:4553 Stock Forecast page.
Towa Pharmaceutical Co., Ltd. reported a fire incident at its Yamagata Plant’s First Solid Dosage Building, which was promptly extinguished with no injuries and minimal material damage. The fire, caused by static electricity igniting dust in a machine room, led to temporary disruptions, but production and shipments are resuming with no expected long-term impact on business performance.
The most recent analyst rating on (JP:4553) stock is a Hold with a Yen3200.00 price target. To see the full list of analyst forecasts on Towa Pharmaceutical Co stock, see the JP:4553 Stock Forecast page.
Towa Pharmaceutical Co., Ltd. reported a fire incident at its Yamagata Plant, specifically in the machine room of the First Solid Dosage Building. The fire, which occurred on July 14, 2025, caused no injuries and only minor material damage to a dust collector. The company has resumed packaging operations and is gradually restoring other processes, with no immediate impact on production and shipment from other buildings. The potential impact on business performance is under review, and stakeholders will be informed if significant effects are anticipated.
The most recent analyst rating on (JP:4553) stock is a Hold with a Yen3200.00 price target. To see the full list of analyst forecasts on Towa Pharmaceutical Co stock, see the JP:4553 Stock Forecast page.
Towa Pharmaceutical Co., Ltd. reported a fire incident at its Yamagata Plant’s First Solid Dosage Building on July 14, 2025. The fire, which was extinguished by the local fire department, caused material damage to the machine room but resulted in no injuries. The company is investigating the cause and assessing the impact on business performance, although other facilities at the plant remain operational.
The most recent analyst rating on (JP:4553) stock is a Hold with a Yen3200.00 price target. To see the full list of analyst forecasts on Towa Pharmaceutical Co stock, see the JP:4553 Stock Forecast page.
Towa Pharmaceutical Co., Ltd. has completed the payment procedures for the disposal of 800 treasury shares as restricted stock compensation, a decision made by the Board of Directors on June 25, 2025. This move involves the allocation of shares to three directors, excluding those in specific roles, and reflects the company’s strategic approach to compensation, potentially impacting its governance and stakeholder relations.
The most recent analyst rating on (JP:4553) stock is a Hold with a Yen3200.00 price target. To see the full list of analyst forecasts on Towa Pharmaceutical Co stock, see the JP:4553 Stock Forecast page.
Towa Pharmaceutical Co., Ltd. has announced details regarding its controlling shareholder, YOSHIDA JIMUSHO, which holds 45.74% of its voting rights. Despite the significant shareholding, the company maintains its independence with no business transactions or influence from YOSHIDA JIMUSHO on its operations.
The most recent analyst rating on (JP:4553) stock is a Hold with a Yen3200.00 price target. To see the full list of analyst forecasts on Towa Pharmaceutical Co stock, see the JP:4553 Stock Forecast page.
Towa Pharmaceutical Co., Ltd. has announced the financial results of its parent company, YOSHIDA JIMUSHO, for the fiscal year ending March 31, 2025. YOSHIDA JIMUSHO, which holds a 40.85% voting rights in Towa Pharmaceutical, is involved in investment, trading, leasing, and real estate management. This announcement provides insights into the financial health and strategic positioning of Towa Pharmaceutical’s parent company, potentially impacting stakeholders’ perceptions and the company’s future operations.
The most recent analyst rating on (JP:4553) stock is a Hold with a Yen3200.00 price target. To see the full list of analyst forecasts on Towa Pharmaceutical Co stock, see the JP:4553 Stock Forecast page.
Towa Pharmaceutical Co., Ltd. has announced a resolution to dispose of 800 treasury shares as part of a restricted stock compensation plan for its directors. This move is designed to align the directors’ compensation with the company’s performance and shareholder value, fostering a long-term increase in corporate value and strengthening shareholder-oriented management.
The most recent analyst rating on (JP:4553) stock is a Buy with a Yen4200.00 price target. To see the full list of analyst forecasts on Towa Pharmaceutical Co stock, see the JP:4553 Stock Forecast page.
Towa Pharmaceutical Co., Ltd. has announced changes in its executive structure following its Ordinary General Meeting of Shareholders and Board of Directors meeting. The reappointments include Itsuro Yoshida as President and Representative Director, and several other directors maintaining their positions, reflecting stability in the company’s leadership. These changes are aligned with the revised Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, indicating a continued focus on regulatory compliance.
The most recent analyst rating on (JP:4553) stock is a Buy with a Yen4200.00 price target. To see the full list of analyst forecasts on Towa Pharmaceutical Co stock, see the JP:4553 Stock Forecast page.
Towa Pharmaceutical Co. has announced several strategic changes, including mergers and revisions to its financial forecasts and business plans. These developments are likely to impact the company’s financial performance and market positioning, reflecting its ongoing efforts to optimize operations and achieve growth targets.
The most recent analyst rating on (JP:4553) stock is a Hold with a Yen3000.00 price target. To see the full list of analyst forecasts on Towa Pharmaceutical Co stock, see the JP:4553 Stock Forecast page.
Towa Pharmaceutical Co., Ltd. has revised its financial objectives for its 6th Medium-term Business Plan (2024-2026) due to better-than-expected financial results for the fiscal year ending March 2025. The company anticipates an increase in operating profit, driven by enhanced production capacity at the Yamagata Plant and improved cost optimization strategies, including R&D expenses. The revisions reflect the company’s commitment to increasing corporate value while maintaining its strategic challenges, policies, and themes.
The most recent analyst rating on (JP:4553) stock is a Hold with a Yen3000.00 price target. To see the full list of analyst forecasts on Towa Pharmaceutical Co stock, see the JP:4553 Stock Forecast page.
Towa Pharmaceutical Co., Ltd. reported a strong financial performance for the year ended March 31, 2025, with net sales increasing by 13.9% to ¥259,594 million and operating profit rising by 31.7% to ¥23,242 million. The company also announced an increase in dividends, reflecting its robust financial health and commitment to returning value to shareholders. The positive results indicate a solid market position and potential for future growth, benefiting stakeholders and reinforcing its competitive stance in the pharmaceutical industry.
The most recent analyst rating on (JP:4553) stock is a Hold with a Yen3000.00 price target. To see the full list of analyst forecasts on Towa Pharmaceutical Co stock, see the JP:4553 Stock Forecast page.